ABSTRACT
Background There are limited population-level data on the pre-exposure prophylaxis (PrEP) care continuum in eastern Africa. Here, we assessed the PrEP care continuum following PrEP rollout in a Ugandan community with ∼40% HIV seroprevalence.
Methods We used cross-sectional population-based data collected between September 3 and December 19, 2018 from a Lake Victoria fishing community in southern Uganda to measure levels of self-reported PrEP knowledge, ever use, and discontinuation following 2017 PrEP rollout via a U.S. President’s Emergency Plan for AIDS Relief (PEPFAR)-supported phased implementation program. Our analysis included HIV-seronegative persons reporting having ever received an HIV test result. We examined associations between demographic, behavioral, and health utilization factors with each outcome using age-adjusted modified Poisson regression.
Results There were 1,401 HIV-seronegative participants, of whom 1,363 (97.3%) reported ever receiving an HIV test result. Median age was 29 years (IQR: 23-36), and 42.3% (n=577) were women. Most (85.5%; n=1,166) participants reported PrEP knowledge, but few (14.5%; n=197) reported ever using PrEP. Among 375 (47.7%) men and 169 (29.3%) women PrEP-eligible at time of survey, 18.9% (n=71) and 27.8% (n=47) reported ever using PrEP, respectively. Over half (52.3%, n=103) of those who had ever used PrEP, self-reported current use.
Conclusion In this Lake Victoria fishing community, there were low levels of PrEP use despite high levels of PrEP awareness and eligibility, particularly among men. Efforts that enhance awareness of HIV risk and increase PrEP accessibility may help increase PrEP use among HIV-seronegative persons in African settings with high HIV burden.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the National Institute of Allergy and Infectious Diseases (grant numbers R01AI143333, R01AI155080, K01AI125086, P30AI094189), the National Institute of Mental Health (grant numbers R01MH107275, R01MH115799, D43TW010557), the Eunice Kennedy Shriver National Institute of Child Health and Human Development (grant number R01HD091003), the Division of Intramural Research of the National Institute for Allergy and Infectious Diseases, and the Presidents Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention (grant number NU2GGH000817). We thank the personnel at the Office of Cyberinfrastructure and Computational Biology at the National Institute of Allergy and Infectious Diseases for data management support.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Research Ethics Committee of the Uganda Virus Research Institute (GC/127/08/12/137) and the Johns Hopkins School of Medicine Institutional Review Board (IRB00217467), and was registered with the Uganda National Council for Science and Technology (HS 540). All RCCS participants provide written informed consent (or assent with parental consent if <18 years) prior to survey participation. This project was reviewed in accordance with CDC human research protection procedures and was determined to be research, but CDC investigators did not interact with human subjects or have access to identifiable data or specimens for research purposes.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Data are available upon reasonable request to the corresponding author and Rakai Health Sciences Program.
